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Abstract
Background: Vital signs measurement can identify pregnant and postpartum women who require urgent treatment
or referral. In low-resource settings, healthcare workers have limited access to accurate vital signs measuring devices
suitable for their environment and training. The CRADLE Vital Signs Alert (VSA) is a novel device measuring blood
pressure and pulse that is accurate in pregnancy and designed for low-resource settings. Its traffic light early warning
system alerts healthcare workers to the need for escalation of care for women with hypertension, haemorrhage or
sepsis. This study evaluated the usability and acceptability of the CRADLE VSA device.
Methods: Evaluation was conducted in community and primary care settings in India, Mozambique and Nigeria and
tertiary hospitals in South Africa. Purposeful sampling was used to convene 155 interviews and six focus groups with
healthcare workers using the device (n = 205) and pregnant women and their family members (n = 41). Interviews and
focus groups were conducted in the local language and audio-recorded, transcribed and translated into English for
analysis. Thematic analysis was undertaken using an a priori thematic framework, as well as an inductive approach.
Results: Most healthcare workers perceived the CRADLE device to be easy to use and accurate. The traffic lights early
warning system was unanimously reported positively, giving healthcare workers confidence with decision-making and
a sense of professionalism. However, a minority in South Africa described manual inflation as tiring, particularly when
measuring vital signs in obese and hypertensive women (n = 4) and a few South African healthcare workers distrusted
the device’s accuracy (n = 7). Unanimously, pregnant women liked the CRADLE device. The traffic light early warning
system gave women and their families a better understanding of the importance of vital signs in pregnancy and during
the postpartum period.
Conclusion: The CRADLE device was well accepted by healthcare workers from a range of countries and levels of
facility, including those with no previous vital signs measurement experience. The device motivated women to
attend primary care and encouraged them to accept treatment and referral.
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Plain English summary
High blood pressure, bleeding and infection affect women
who are pregnant, in labour or have recently given birth.
Abnormal blood pressure and pulse measurements can
indicate that a woman has one of these conditions and
may require treatment. Healthcare workers in low-income
countries often lack the equipment and training to measure
and understand blood pressure and pulse. The CRADLE
Vital Signs Alert is a novel device that accurately measures
blood pressure and pulse and is suitable for low-resource
settings. Traffic lights within the device help healthcare
workers identify women who need additional treatment for
these conditions.
This study evaluated whether the CRADLE device was
easy-to-use and preferred to other devices. One hundred
and fifty five interviews and 6 focus groups involving
community- and facility-based healthcare workers and
pregnant women and their family members in India,
Mozambique, Nigeria and South Africa were conducted.
The healthcare workers reported the CRADLE device
was easy-to-use. The traffic lights enabled them to make
decisions about treatments and made them feel more
professional. A minority of healthcare workers in South
Africa said the device was tiring to use and questioned
its accuracy. The women and their families reported that
the traffic lights enabled a better understanding of their
health. It encouraged them to attend their appointments
and accept treatment. Overall, the CRADLE device was
well accepted by healthcare workers and pregnant women
from a range of countries and levels of facility.
Background
Vital signs measurement is one of the most important
screening tools in antenatal care, identifying those who
require urgent treatment, delivery or referral. Despite its
clinical importance, in low-resource settings healthcare
workers (HCWs) often have limited access to functioning,
accurate devices appropriate for their environment [1].
Even when appropriate equipment is available, the level of
training required to accurately measure and act on vital
sign measurements (including blood pressure (BP) and
pulse) is often lacking. These barriers contribute to
avoidable maternal and perinatal mortality and morbidity,
which are most prevalent in low-resource settings [2].
The Microlife® CRADLE (Community blood pressure
monitoring in Rural Africa & Asia: Detection of
underLying pre-Eclampsia and shock) Vital Signs Alert
(VSA) is a hand-held, upper-arm, semi-automated device
measuring BP and pulse. The device has been accuracy
validated in pregnancy, including pre-eclampsia and
hypotensive pregnancies, according to formal validation
protocols [3, 4]. It meets the World Health Organization’s
criteria for low-resource settings, being robust and portable,
having low power requirements (charging through a micro-
USB port), requiring minimal calibration, and being
affordable at $25 USD per unit [5]. The CRADLE VSA
has been further modified, incorporating a traffic light
early warning system (EWS) [6, 7], aiming to alert
HCWs and untrained users to vital sign abnormalities
secondary to pre-eclampsia, obstetric haemorrhage and
sepsis (the three leading causes of maternal mortality
worldwide) [2]. The EWS triggers for hypertension are
well-established thresholds of BP used in clinical practice.
The EWS triggers for obstetric haemorrhage and sepsis
were determined through retrospective analysis of vital
signs in women with haemorrhage; shock index (pulse/
systolic BP) thresholds were found to be consistently
reliable markers of compromise [6, 7]. The predictive
ability of the hypertension and shock index EWS
thresholds were prospectively validated in women from
low- and middle-income countries with either pre-
eclampsia, obstetric haemorrhage or sepsis, the results
of which are described elsewhere (In Press). Although
the current model of the CRADLE VSA does not have
mHealth capabilities, incorporation of mHealth technology
to future models of the CRADLE VSA is possible (i.e.
transmission of vital signs data from the device to mobile
phones or directly to a central facility).
By enabling HCWs in low-resource settings to have
better access to accurate vital sign measurement, the
CRADLE VSA addresses the three delays model of
maternal mortality and morbidity [8]. The model is a
conceptual framework describing the three delays in
receiving care that can result in avoidable maternal
mortality and morbidity: (i) delays in the recognition of
the maternal health problem and decision to seek care;
(ii) delays in reaching the health facility; (iii) delays in
the provision of adequate care. The CRADLE VSA aims
to identify those who require urgent referral (the second
delay) and once at facility, it aims to identify those who
require urgent intervention and monitor response to
intervention (third delay). In recent years, with improved
access to mobile phones, even in the most remote areas of
the world, mobile health (mHealth) technologies and other
patient monitoring devices are becoming important tools
in maternal and perinatal health [9]. Despite improved
access to these technologies, formal evaluation of how
devices are integrated into routine care [10], contextual
evidence on health care workers’ barriers and facilitators
and their impact on clinical outcomes is limited [11, 12].
Lessons learnt from a recent large-scale study to improve
healthcare in rural India demonstrated the importance of
careful evaluation of how innovations might evolve during
implementation and how users adapt to the innovations
during scale-up [13].
Prior to implementation at scale, it is important to
consider the theory of diffusion of innovation, first
described by Everett Rogers in 1962 [14], and the five
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categories of influence, that may be relevant to the
implementation of the CRADLE VSA:
 Relative advantage, which is the degree to which
an innovation is perceived as better than the idea it
supersedes (includes economic advantage,
convenience and satisfaction)
 Compatibility with existing values and practices,
which is the degree to which the innovation is
perceived as being consistent with the values, past
experiences, and needs of potential adopters
 Simplicity and ease-of-use
 Trialability, which is the degree to which the
innovation can be experimented with (a trialable
innovation represents less risk to the individual who
is considering it)
 Observable results: the easier it is for an individual
to see the results of an innovation, the more likely
they are to be adopted
This qualitative study aimed to determine the usability,
feasibility and acceptability of the CRADLE VSA among
a variety of users and in diverse socio-economic settings,
considering these five clusters of influence. This will
inform future device modifications and successful dissem-
ination of the CRADLE VSA for routine use.
Methods
Study area
The evaluation was conducted in two separate studies,
in the community and primary health centres in multiple
study areas in India [15], Mozambique [16] and Nigeria
[17], and tertiary hospitals in South Africa. The CRADLE
device was developed for use by all levels of HCW. A
variety of settings were included in this study to ensure
transferability of the findings and relevance for scale-up.
Evaluation in India and Mozambique was embedded in
the Community Level Intervention for Pre-eclampsia
(CLIP) Trial (NCT01911494) [18], a cluster randomised
control trial evaluating a package of interventions including
the CRADLE device, with evaluation in Nigeria being part
of a process evaluation run alongside the trial. Details of
each CLIP trial area are described elsewhere [15, 16, 19].
Evaluation in South Africa was embedded in the CRADLE
2 study, a mixed-methods observational study evaluating
the CRADLE VSA and the predictive ability of its traffic
light EWS. This study took place in tertiary centres, where
the rate of adverse outcomes including eclampsia and
hysterectomy were high, to effectively evaluate the traffic
light thresholds in a high-risk population. These centres
cared for women requiring either secondary- or tertiary-
level care. In India and Mozambique, a prototype of the
CRADLE VSA, with the same accuracy and features
suitable for low-resource settings but without the traffic
light EWS, was tested; in Nigeria and South Africa, the
modified CRADLE VSA, with traffic light EWS, was
assessed. For each study, HCWs were trained to use the
device through short demonstration and practical ses-
sions. The CLIP trial took place over 33 months (be-
tween February 2014 and February 2017). The CRADLE
2 study took place over 15 months (between January 2015
and April 2016).
Study design
Qualitative evaluation of the CRADLE VSA (and its pre-
decessor: Microlife 3AS1–2) followed the Framework
Method [20] to determine the usability, feasibility and
acceptability of the CRADLE device and the COnsolidated
criteria for REporting Qualitative research (COREQ) Check-
list was used to report the methodology and findings [21].
The qualitative evaluation comprised of two phases,
the first at 3 months into the studies and the second at
9 months for the CRADLE 2 study in South Africa and
12 months into the CLIP Trial (Table 1). Including two
time points allowed for exploration of evolving experience
using the device over time [22]. At least 9 months into the
study was deemed adequate time for longer-term issues to
become apparent. Purposeful sampling was used to
identify participants with a broad range of experiences
across sites [23]. Snowball sampling was used to ensure
views from a variety of pregnant women and family
members [24]. CLIP and CRADLE study participants
were approached face-to-face and given information sheets
specific to the qualitative evaluation and signed an
additional consent form to participate in the evaluation.
The study comprised of semi-structured interviews
[25] and focus group discussions [26] with community-
and facility-level HCWs equipped with and trained to
use the device and pregnant women and their family
members who had come into contact with the device.
Community HCWs included Auxiliary Nurse Midwives
(ANMs) and Accredited Social Health Activists (ASHAs)
in India, Agente Communitarios de Saude (APEs) in
Mozambique and Community Health Extension Workers
(CHEWs) in Nigeria. At each site, experienced research
staff were locally recruited and trained to conduct the
interviews and focus group discussions, with guidance
from senior social scientists (JS, KM, HB, DA, UC). The
research staff were selected due to their familiarity with
the community, the CRADLE device and the research
question. Each interview and focus group discussion was
conducted in the participant’s workplace or home and in
either their respective country official language or the
local language, according to the participants preference,
by one interviewer and was audio-recorded. Participants
were approached to participate in either a semi-structured
interview or a focus group discussion, with no one partici-
pating in both.
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Data management and analysis
All data collection was led by the local team at each site
and coordinated by the CRADLE study coordinator and
principal investigator in the UK. The field staff transcribed
and translated the data to English verbatim. Accuracy was
ensured by comparing the audio recording to the tran-
scripts. The data was coded and thematically analysed
using NVivo version 10 [QRS, Vic, Australia] by four
researchers, both from local sites and coordinating institu-
tions. The four researchers worked independently on four
NVivo projects, each with identical coding structures
to allow for merging to a single project on completion.
The researchers convened regularly (via Skype) to
ensure agreement in coding between researchers, dis-
cussing emerging themes and to reflect on the findings.
The NVivo software coding agreement function (Kappa
coefficient) was used to assess agreement between coders.
If coding agreement was less than 93%, coding disagree-
ments were discussed during Skype meetings until the
researcher group reached a consensus. Factors that may
have facilitated or hindered the usability, feasibility and
acceptability of the device and those factors likely to influ-
ence its potential translation to routine use were explored.
While NVivo nodes were created to reflect the emerging
themes from participants’ discourse that could be linked
to these constructs, the participants and the specific
contexts in which such discourses were developed were
categorized and labelled by attributes that reflected the
age, site, phase of the study, model of device used, years
of experience and level of care. Through further coding,
similarities and differences within, between and among
these groups were compared and common and divergent
patterns of responses were explored.
For phase 1, a deductive approach was used, with themes
identified through previous researcher experience of device
use. For phase 2, additional themes were iteratively
determined through researcher consensus in response
to emerging themes from phase 1 interviews, using an
inductive approach. Field notes were not taken and data
saturation was not assessed during the data collection.
A large sample size was needed to understand the
country context influence in community, primary and
tertiary health centres and data saturation was achieved
(sample size shown in Table 1).
Ethical considerations
The study received ethics approval from KLE University,
Belgaum India (MDC/IECHSR/2011–12), the CISM
Institutional Review Board, Mozambique (CIBS_CISM/08/
2013), the Olabisi Onabanjo University Teaching Hospital,
Sagamu Nigeria (OOUTH/DA/326/431), University of
Stellenbosch, South Africa (N14/06/068), University of
Table 1 Interviews and focus group discussions distribution across sites
Sites: Mozambique
(24 month CLIP trial)
India (33 month CLIP trial) Nigeria (33 month CLIP trial) South Africa
(12 month CRADLE study)
Device Prototype CRADLE VSA Prototype CRADLE VSA CRADLE VSA CRADLE VSA
Facility level Primary health centre
and home
Primary health centre and home Primary health centre Tertiary hospital
Number of study areas 2 2 2 3
Participants Agente Communitarios
de Saude (APEs)
Auxiliary Nurse Midwives (ANMs) and





Nurses Nurses Nurses Nurses
Doctors
Pregnant women Pregnant women and
family members
Phase 1
Timing from start of
trial/study
3 months 3 months 3 months 3 months
Number of interviews 29 10 12 25
Number of focus
groups
0 0 2 0
Phase 2
Time from start of
trial/study
12 months 12 months 12 months 9 months
Number of interviews 42 10 12 15
Number of focus
groups
0 0 2 2
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Cape town, South Africa (401/2014), University of Free
State, South Africa (230408–011), as well as by the
UBC C&W Research Ethics Board in Canada (H12–00132).
Results
In total, 155 interviews and six focus group discussions
were conducted in India, Mozambique, Nigeria and
South Africa. Interviews included 114 HCW participants
and 41 pregnant women and family members (see Tables 1,
2 and 3). Interviews lasted between 30 and 60 min.
Of the 114 HCWs interviewed, all were either commu-
nity HCWs, nurses, midwives, or clinical assistants. 35%,
30 and 35% of HCWs interviewed cared for women in
their homes, primary health centres and tertiary hospitals,
respectively, and 87% of HCWs interviewed were female.
The six focus groups comprised of six to eleven partici-
pants. Of the 50 HCWs who took part, all were either
community HCWs, nurses, midwives, or clinical assistants;
66% worked in primary health centres and 34% worked in
hospital; all HCWs included in the focus groups were
female. For more details on participant characteristics see
Tables 2 and 3.
Qualitative analysis of the interviews and focus group
discussions revealed several major themes across countries
and some country-specific themes.
Healthcare worker opinion on ease-of-use
The view held by most HCWs was that the CRADLE
device was easy to use and, for those with prior experience
measuring vital signs, preferred to their prior device.
Those with previous mercury sphygmomanometry
experience
For all HCWs with previous mercury sphygmomanometry
experience (the majority), it was agreed that CRADLE
device measurement was simpler and quicker. Sphygmo-
manometry was reportedly technically difficult, often
required repeating to achieve a BP reading and the HCW
risked appearing inexperienced. Some reported that
measurement was now less stressful. Across all sites,
HCWs expressed relief not to need a stethoscope for
measurement, because it was often difficult to hear the
heart sounds in busy environments and it was painful for
Table 2 In-depth interview participants’ demographic
information





Mozambique 35 (31%) 36 (88%)
India 20 (18%) 0 (0%)
Nigeria 19 (17%) 5 (12%)
South Africa 40 (35%) 0 (0%)
Facility level
Community 40 (35%) NA
Primary health centre 34 (30%) NA
Hospital 40 (35%) NA
Age (years)
15–20 1 (1%) 6 (15%)
21–30 36 (32%) 16 (39%)
31–40 37 (32%) 15 (37%)
41–50 25 (22%) 2 (5%)
51–60 13 (11%) 2 (5%)
Missing 2 (2%) 0 (0)
Gender
Female 99 (87%) 39 (95%)
Male 14 (12%) 2 (5%)
Missing 1 (1%) 0 (0%)
Years of experience
0–5 41 (36%) NA
6–10 38 (33%) NA
11+ 27 (24%) NA
Missing 8 (1%) NA
a33 pregnant women, 8 family members
Table 3 Focus group participants’ demographic information
Characteristics Healthcare workers (%) n = 50
Country
Nigeria 33 (66%)
South Africa 17 (34%)
Facility level
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their ears. In Nigeria, HCWs reported that previously they
had not known when to stop inflating the cuff (which,
according to the HCW, was painful for the woman), but
with the CRADLE device, the sound alerts indicated when
to stop inflating. Some favoured the CRADLE device
because it gave exact numbers, compared to sphygmoma-
nometry, which required user approximation. One HCW
admitted resorting to guessing the BP using sphygmoma-
nometry because it was too challenging, illustrated in the
quote below:
“At times the mercury maybe moving in a scattered
manner. So [...] we will not be able to get the accurate
reading, we would rely on assumption or guessing by
asking the patient if she’s sleeping very well, if she does
not have headache, so we may we assume that the
patient does not have high blood pressure. That thing
affects our work, because at the end of the day the
patient may have hypertension.” Focus group
discussion, CHEW, Nigeria.
Unanimously HCWs preferred the simultaneous auto-
mated pulse measurement, rather than having to manually
measure pulse. For those measuring vital signs in women’s
homes, the CRADLE device was smaller, easier to carry
and more robust than their prior device. Most community
HCWs in India and Mozambique (ASHAs, ANMs, and
APEs) had no previous experience measuring vital signs,
whereas community HCWs in Nigeria (CHEWS) had pre-
vious experience. For those with no previous experience
measuring vital signs, it was noted that although they were
initially daunted by the new equipment, after simple
training, it became easy-to-use.
Those with previous automated devices experience
HCWs in the South African hospitals often had previous
experience with sophisticated automated devices that
could perform repeated measurements automatically and
had been used in their departments for many years. The
majority, however, reported that they liked the CRADLE
device equally or more than the automated devices. For
seven HCWs in South Africa, there was a perception of
taking a step backwards. Of those, four HCWs described
manual inflation as tiring and painful, particularly when
measuring vital signs in obese and hypertensive women
(requiring more inflation). The same four HCWs also
reported BP measurement was slower and that, unlike
automated measurement, other tasks could not be done
simultaneously. Six of the seven HCWs with negative
views, reported confusion about inflation, which would
result in errors, particularly in obese and hypertensive
women. When probed, the descriptions indicated a lack of
understanding of the symbol that represented the need for
additional inflation. Of those seven HCWs with predom-
inantly negative views, five were 41–50 years old and five
had eleven or more years’ of experience.
Healthcare worker opinion on the CRADLE device
accuracy
In women’s homes and primary health centres in
Mozambique, India and Nigeria the CRADLE device
was perceived to be accurate. This perception was
strengthened over time, demonstrated through a greater
proportion of references regarding accuracy in phase 2
compared to phase 1. Accuracy was often assumed due
to its “high-tech” and “modern” appearance. One HCW
attributed her perceived increase in the incidence of
hypertension she was detecting to the device’s accuracy.
Another thought the device was accurate because it
gave similar readings to a device she used at home.
“As we are getting more experience we are liking this
apparatus more. Now we know that to detect one case
of hypertension we have to check everyone’s BP
frequently. As days are passing our faith on machine
and accuracy of recording BP has increased
tremendously.” Interview, ANM, India.
In South Africa, views on accuracy varied, with a few
South African HCWs distrusting the CRADLE device’s
accuracy (n = 7). Reasons for doubting the accuracy
included variations in BP minute-to-minute and seeing
more women with hypertension since using the CRADLE
device (a reason for assuming accuracy for others). Seven
percent of South African HCWs (2% of all HCWs, n = 4),
some of whom also questioned BP accuracy, reported that
the CRADLE device overestimated pulse in comparison to
manual palpation.
The chief nurse at one South African hospital
suggested that the accuracy concerns were only in very
busy areas of the hospital where staff were dealing with
high volumes of patients and struggling with the
workload.
“Now my assumption is that this [CRADLE device]
isn't suitable for the high number of patients we have.
You know, it's 24/7, a lot of people per day. It seems
like the places where people distrust the device the
most are the busiest place.” Focus group discussion,
Chief nurse, South Africa.
Another nurse at the same hospital affirmed this view:
“And it could be a perception, because if you have to
pump […] 200 patients, and you don't get accurate
readings, […] that makes it hard to believe in these
machines, because you don't like it, because you have
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to work so hard. So, then, the variability is so big. So it
might be true, but if you have to pump 3, 4 times for
one patient, you get negative from the start.” Focus
group discussion, Nurse, South Africa.
The majority in South Africa trusted the accuracy of the
CRADLE device. Some acknowledged that the perceived
increase in hypertension may be because their previous
devices were underestimating BP. Others acknowledged
that occasional unexpected BP readings may have been
linked to incorrect technique rather than the device itself.
Healthcare worker opinion on the CRADLE traffic light EWS
In Nigeria and South Africa, the sites with the CRADLE
device with traffic lights, the traffic lights EWS were
unanimously perceived positively. Many of those trained
to interpret the numbers reported that, although they
relied on the numbers, the traffic lights were a useful
addition. The traffic lights reassured the HCW on their
decision to escalate care, giving them confidence to act
quickly. For some, the traffic lights would alert to a
problem that would have otherwise been missed. For
those with more limited training i.e. community HCWs,
the traffic lights were even more useful. These views are
illustrated in the quote below:
“[The traffic lights are] very useful. It’s just like the
traffic light we see on the road, because it will tell you
when you are supposed to go, when you are supposed
to stop, when there is danger sign. So the one seen on
[CRADLE device], it will tell okay, this patient is okay,
or that you have to refer this patient as fast as
possible. So it is very useful.” Interview, Nurse, Nigeria.
Some reported the traffic lights made counselling of
women easier, with the lights being used to illustrate the
problem and encourage acceptance of referral or treatment.
These views were particularly strong in comparison to
sphygmomanometry, a process that restricted involvement
of the women in the management of their health.
“The [traffic lights] have always been of significant
help to the midwives. You can easily educate them
using the traffic lights on the device and tell them if
they need some care. You can even go as far as using
another patient with a normal BP as an example.”
Interview, Senior nurse, Nigeria.
Healthcare worker opinion on impact on work-life
A consistent theme from Mozambique, India and Nigeria
HCWs was the sense of professionalism and job satisfac-
tion that the CRADLE device had given them. Many
described feeling proud and confident when using the
device and become more respected in the community.
The device aided communication with senior HCWs
and gave them a sense of empowerment to make
clinical decisions. These feeling were expressed in the
following two quotes:
“Before we used to get confused about BP so we used to
ask our senior doctors to check the BP again as we are
getting high BP. Now we are confident in telling our
seniors that ‘I have detected one HDP case so please
do the needful’.” Interview, ANM, India.
HCWs reported that the device made it easier to per-
suade women to be referred when there was a problem.
Although the CRADLE device may have encouraged
more women to attend primary health centres, they do
not associate the device with a heavier workload because
the device identified problems earlier, thereby reducing
their subsequent workload arising from complications.
“For me, it has a positive impact […], truly speaking it
reduces my workload […]. For example, if someone
suffers from high blood pressure and it gives her
convulsions. I think it is two times better to work for
20 women rather than only one who gives you a hard
time because it is necessary to have medicine to treat
the convulsions, we might lose her.” Interview, Nurse,
Mozambique.
In South Africa, although the majority agreed that vital
signs measurement was now quicker, 8 HCWs reported
that due to perceived errors, difficulties measuring BP in
hypertensive women, and inability to do other tasks
whilst measuring vital signs, workload had increased.
“It is actually more time consuming when you need to
pump it up because when you are pumping up you
could have done something else for your patient, like
the temperature reading, or make your patient
comfortable or something. And now I have to stand
and normally while the blood pressure is reading I
speak to the patient to find out how the patient is
doing and then we do our notes and we do our
recordings.” Interview, Nurse, South Africa.
HCW-reported technical issues and errors
In Mozambique and India the CRADLE device was
powered by replaceable batteries. Unanimously, HCWs
reported that battery life was adequate, lasting 2–3 months
depending on intensity of use.
In Nigeria and South Africa, the CRADLE device
charged via a micro-USB port. In Nigeria, one charge
lasted 2–4 weeks, depending on intensity of use. Charging
was dependent on electricity availability, which often
resulted in the device being charged when electricity
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became available, regardless of the battery life. At the
South African hospitals, reliable electricity was not a
concern. HCWs would charge the device whenever it was
not in use and would take it off charge before it was fully
charged. For this reason, it was not possible for HCWs to
judge how long one charge lasted as it was rarely allowed
to run flat. Some reflected this was done out of habit,
because it is how they charged their previous automated
BP devices and other ward equipment.
On switching on the device, the ‘low battery’ symbol is
displayed, as are all other symbols. In Nigeria and South
Africa, there was some confusion regarding the ‘low
battery’ symbol. When probed, responses suggested
confusion between the display shown immediately upon
switching on the device and a true ‘low battery’ symbol
which flashes throughout vital signs measurement.
These findings demonstrate that the display can mislead
the user into thinking the device needs charging more
frequently than is required and will be fed back to the
manufacturers.
Three percent of all HCWs (n = 5) reported mechanical
issues requiring replacement. Problems included a broken
hand pump, broken tubing and three broken charging
ports. In South Africa, charging cables (generic micro-
USB chargers, also used for most mobile phones) needed
to be replaced frequently. Even so, HCWs preferred mi-
cro-USB charging to replaceable batteries, as electricity is
more readily available than new batteries.
There were very few reports of errors. Some
acknowledged that errors were associated with com-
promised technique e.g. movement. 6% of all HCWs
(n = 10) thought errors were more frequent when the
battery was low rather than considering well-established
causes of errors. Many expressed that they appreciated
the error alerts on the CRADLE device, explaining that
with mercury sphygmomanometry errors occurred
without their knowledge. This was illustrated in the
quote below:
“And if we have made any mistake, [the CRADLE
device] will show error. If we have made a mistake, we
can see the suggestions and repeat it again. In that one
you cannot. We don’t realise. We might think that we
are not able to hear and so we keep inflating
repeatedly.” Interview, ANM, India.
Opinions of the women and their families
Unanimously, pregnant women liked the CRADLE device.
The device gave them and their families a better under-
standing of the importance of the measurement of vital
signs in pregnant and postpartum women because, unlike
sphygmomanometry, they could see the numbers (and the
traffic lights, depending on the site). This was reiterated
by the HCWs.
“If they are educated, they see and ask how much [the
BP] is. We hold it in front of them and show them.
[HCW]: ‘See this is your BP.’ [Patient]: ‘It is good that
you come, check and show us. If we go to [the
hospital], they don’t tell us anything. They only write it
down and give it. Only when we ask them ourselves,
they tell us. If we cannot read, we cannot make out.
But you explain it to us, come all the way here, check
and tell us how much it is.’” Interview, ASHA, India.
Community HCWs could measure vital signs in the
woman’s home using the CRADLE device (previously
difficult because mercury sphygmomanometry was less
portable). Women and their families saw this as a positive
change because they no longer needed to travel to health
centres.
Like many HCWs, the pregnant women assumed accur-
acy due to its digital function and modern look. It was
perceived as an improvement in the antenatal service
provided at primary health centres and was resulting in
more women attending centres. Family members also felt
positively about the device, even asking if their vital signs
could be measured.
“My husband liked it, because he felt that the level of
care I now receive has improved compared to the ones
I received during the previous pregnancies. He was
happy and prayed for those who introduced the
[CRADLE] device.” Interview Pregnant woman,
Nigeria.
Discussion
These findings demonstrate that the CRADLE device
was easy-to-use by all levels of HCW and well accepted
by the vast majority, despite some having never measured
vital signs previously. Technical modifications, including
the traffic light early warning system and micro-USB
charging, to ensure suitability for community HCWs in
low-resource settings were of benefit to users. The traffic
light EWS was appreciated by all, even those with prior
training to respond to vital sign thresholds.
The findings also highlighted minor technical issues
that need to be addressed prior to scale-up, either by
requesting manufacturing adaptations or by improving
device training.
Strengths of this study include the range of countries,
levels of facility, HCWs experience and training and the
different studies hosting the evaluation. A sufficient
number of interviews and focus groups ensured theoretical
saturation and having two phases of data collection (at
3 months and 9 or 12 months) allowed for temporal
variations to be explored. The study gives an extensive
and diverse range of views increasing the likelihood of
transferability. In addition, all data was collected by
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local researchers with familiarity of the region and socio-
cultural context, some of whom also participated in the
analysis.
A limitation of the study is the potential impact of
social desirability bias. Participants were aware of their
role in the study and the objective to explore their
views related to the CRADLE device. Participants may
have perceived the researcher as a person of power,
aiming to portray the CRADLE device as a success, which
may have influenced participant responses. To minimise
this, specific instructions regarding the purpose and confi-
dentiality of the interviews were explained.
The influence of researcher reflexivity was considered
[27, 28]. Some of the researchers worked on other aspects
of the study and had extensive understanding of the
CRADLE device. Throughout the research process, the
researchers considered their own opinions of the device,
their relationship with the participants and the influence
on the data generated. Although they may have taken a
different emphasis from that of independent observers,
detailed exploration of the facilitators and barriers was
possible due to a good understanding of the intricacies of
the device.
The majority of studies evaluating BP devices focus on
accuracy, describing quantitative validations. Very few
studies have evaluated the usability and acceptability of de-
vices, or assessed the problem from the user’s perspective
rather than the developer’s perspective, these being critical
for successful implementation. The only published studies
to qualitatively evaluate BP devices in the hands of users are
studies of home BP monitoring and telehealth in high-
income countries, exploring the use of BP devices in the
hands of patients rather than HCWs [29–32]. This study is
unique in that it explores the opinions of a variety of HCWs
from a number of low- and middle-income countries.
The study findings can be explained following the
diffusion of innovation model and the impact of the five
categories of influence the model describes [14].
Relative advantage, simplicity and ease-of-use
In Mozambique, India and Nigeria, the CRADLE device
was perceived as a welcomed resource improvement
compatible with existing routines, despite differences in
level of experience, training, and working-environment
across sites. Their previous BP device experience was
more varied, with some having used automated devices
but most having only used mercury sphygmomanometry.
The CRADLE device was perceived as more techno-
logically advanced and easier-to-use than their previous
equipment and accuracy was presumed.
Observable results
In Mozambique, India and Nigeria, the device improved
confidence and job satisfaction for many HCWs. The
device empowered lower cadres of HCW to undertake
their work with confidence and the traffic lights were
reported to improve escalation of care for all cadres of
HCW. The traffic lights also gave women a better
understanding of their health and the need for vital
signs monitoring. This led to the perception that more
women chose to attend primary health centres and easier
counselling of women who needed urgent treatment or
referral.
Compatibility with existing values and practices
Across the sites, HCWs reported that although more
women attended health centres because of the device,
this did not negatively impact on their workload as the
device enabled complications to be identified and treated
promptly. Rather than perceiving the immediate burden
of having more women to attend to, these HCWs were
valuing the longer-term gains of the device. This is an
important finding, which can be utilised when transmit-
ting the value of the CRADLE device to other HCWs at
scale-up.
In South Africa, although the majority thought posi-
tively, a small proportion of HCWs disliked the CRADLE
device and questioned its accuracy. These HCWs worked
in very busy units, measuring vital signs many times a day,
having previously relied on sophisticated (but necessarily
validated or accurate) automated machines. Manual
inflation with the CRADLE replacement was perceived
as a step backwards and resulted in resentment of the
CRADLE device. Although the CRADLE device is more
accurate than their existing devices, the HCWs associated
their sophisticated machines with better accuracy. Their
existing workload and previous device experience influ-
enced their opinions. This lack of awareness of device
accuracy can be described as a barrier to successful uptake
[33]. Of note, they questioned CRADLE device accuracy
specifically in those requiring more manual inflation
(obese and hypertensive women). BP measurement can be
more challenging in these women. These isolated negative
experiences can impact on successful implementation and
can be difficult to overcome [33, 34].
In South Africa, older age emerged as a barrier to
adoption in this study, perhaps due to resistance to
change rather than fear of technological complexity. The
younger respondents were more adaptable to the novel
technology, whereas the older respondents were comfort-
able with their existing devices and resistant to change in
their routines. Age has also been identified as a barrier
to the uptake of technology in other studies [33, 35].
Older users may need additional training and support
to improve adoption.
Across the Mozambique, India and Nigeria sites and
at two of the three South African sites, there was a
strong researcher presence and support system. At these
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sites, research staff could assist and reassure HCWs using
the new technology and educate on the importance of
accurate devices. Successful implementation at the other
South African site may have been hindered by the limited
technical support. Similar barriers have been demon-
strated in other studies evaluating the implementation
of newly adopted health technologies [33].
Implications for clinicians and policy-makers
This study has demonstrated the importance of training
and support when implementing a new technology. It
has also highlighted aspects of the CRADLE device that
require more focused education (accuracy, inflation,
charging). Considering these findings, a simple training
package that is transferable across settings and comple-
ments the simplicity of the device is designed for scale-up.
The perception of the user plays a crucial role in the
innovation process [34]. This study has shown that existing
workload and previous experience should be considered as
context-dependent barriers and facilitators to implementa-
tion at scale. The study suggests that in relatively busy and
well-resourced areas, such as South African tertiary cen-
tres, fully-automated vital signs devices, that automatically
and regularly repeat readings, may be more appropriate, if
accuracy has been confirmed. The traffic light EWS, how-
ever, remains a useful component even amongst trained
staff. An automated version of the CRADLE device may be
better suited in these settings.
The CRADLE VSA was designed for use by community
HCWs to identify pregnant and postpartum women who
require urgent intervention and referral. When considering
the CRADLE device in the context of the three delays
model of emergency obstetric care, it was designed to
address the second and third delays (identifying and reach-
ing health facility and receiving adequate and appropriate
treatment) [8]. Reflecting this, HCWs reported that the
device enabled identification of women needing interven-
tion, who might have otherwise been missed and that the
traffic light EWS encouraged the decision for escalation of
care. This device has the potential to strengthen task-
sharing approaches and may improve the quality and safety
of care women receive. An unanticipated finding from our
study was that the CRADLE VSA could also address the
first delay (deciding to seek care). Women were motivated
to attend because of the new technology. The visual traffic
light triggers gave the women a better understanding of
the importance of screening and assisted in explaining the
meaning of abnormalities and encouraged acceptance of
life-saving treatments and referral to higher-level facilities.
A major influencer of poor antenatal care attendance is
experience of poor-quality care [30, 36]. The introduction
of the CRADLE VSA to facilities may enhance perceptions
of high quality care and encourage better antenatal attend-
ance, which would be of interest to policy-makers.
Conclusions
This study enabled better understanding of the facilitators
and barriers to use of the CRADLE VSA. The CRADLE
device was well accepted by healthcare workers from a
range of countries and levels of facility, including those
with no previous vital signs measurement experience. The
device motivated women to attend primary care and
encouraged them to accept treatment and referral. These
findings could be used to guide scale-up.
The device was designed to identify women who are at
risk of avoidable maternal morbidity and mortality and
prompt escalation of care. Although this study demon-
strated that the device is acceptable and of benefit to
HCWs, it is not known whether this will be translated to
reductions in maternal mortality and morbidity. The
CRADLE 3 Trial is underway across ten low-income
country sites to determine the impact that the CRADLE
VSA and a simple training package implemented at
community, clinic and hospital level, has on maternal
mortality and severe morbidity.
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